Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3375880 · 2 trials · 1 indication
The pain VAS is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the scale from 0 mm (no pain) to 100 mm (severe pain).
PK: Cmax of LY3375880
PK: AUC of LY3375880
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Part A: LY3375880 Formulation A | EXPERIMENTAL | LY3375880 Formulation A administered subcutaneously (SC). |
| Part A: LY3375880 Formulation B | EXPERIMENTAL | LY3375880 Formulation B administered subcutaneously SC. |
| Part A: LY3375880 Formulation C | EXPERIMENTAL | LY3375880 Formulation C administered SC. |
| Part A: Positive Control | PLACEBO_COMPARATOR | Positive Control (buffer matrix, only) administered SC. |
| Part B: LY3375880 Test 1 | EXPERIMENTAL | LY3375880 Test 1 Formulation administered SC. |
| Part B: LY3375880 Test 2 | EXPERIMENTAL | LY3375880 Test 2 Formulation administered SC. |
| Part B: LY3375880 Test 3 | EXPERIMENTAL | LY3375880 Test 3 Formulation administered SC. |
| LY3375880 Single Dose | EXPERIMENTAL | Single dose of LY3375880 administered IV or SC |
| Placebo Single Dose | PLACEBO_COMPARATOR | Single dose of placebo administered IV or SC |
| LY3375880 Multiple Dose | EXPERIMENTAL | Multiple doses of LY3375880 administered IV or SC |
| Placebo Multiple Dose | PLACEBO_COMPARATOR | Multiple doses of placebo administered IV or SC |
| Name | Type | Description |
|---|---|---|
| LY3375880 | DRUG | Administered SC |
| Buffer Matrix (No LY3375880) | DRUG | Administered SC |
| Autoinjector (AI) | DEVICE | AI used to administer LY3375880 or Buffer Matrix |
| Manual Syringe | DEVICE | Manual syringe used to inject LY3375880 |
| LY3375880 IV | DRUG | administered IV |
| LY3375880 SC | DRUG | administered SC |
| Placebo IV | DRUG | administered IV |
| Placebo SC | DRUG | administered SC |
Inclusion Criteria: * Are overtly healthy males or females, as determined by medical history and physical examination * Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²) inclusive * Females who are not of child-bearing potential * Males who agree to use a reliable method of...
LY3375880 is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development for healthy participants. The drug is being studied in early-stage trials to evaluate its safety, tolerability, and pharmacokinetics.
LY3375880 is being studied in healthy participants as part of Phase 1 clinical trials. The studies are designed to assess the safety, tolerability, and how the drug behaves in the body. It is not yet approved for any medical condition and remains in clinical development.
LY3375880 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting Phase 1 clinical trials to evaluate the drug in healthy participants.
LY3375880 is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy participants. The drug is investigational and has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in early-stage studies.
LY3375880 has been studied in two completed Phase 1 clinical trials. NCT03343587 enrolled 80 healthy participants in the United States, and NCT03913260 enrolled 83 healthy participants to evaluate different injectable formulations. Both trials were placebo-controlled and double-blind.
LY3375880 is a unique investigational compound developed by Eli Lilly and Company. No alternative names for this drug have been reported. It is being studied under its own identifier in clinical trials and is not known to be identical to any other marketed medication.